Pharmaceutical intermediates

Ticagrelor Intermediates

7 pharmaceutical intermediates for Ticagrelor. Indication: Stroke; Acute Coronary Syndrome ; Myocardial Infarction; Peripheral Vascular Disease.

About Ticagrelor

Originator: AstraZeneca
Indication: Stroke; Acute Coronary Syndrome ; Myocardial Infarction; Peripheral Vascular Disease
Approved Date: 09/03/2015
DS/DP: 04/30/2025

7 intermediates currently listed for Ticagrelor. Request specifications, documentation or a quotation for any item below.

Ticagrelor intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
4,6-Dichloro-2-(propylthio)pyrimidin -5-amine	145783-15-9	/	/
2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro -3aH-cyclopenta[d][1,3]dioxol -4-yloxy)ethanol L-tataric acid	376608-65-0	/	/
(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanaminium(2R)hydroxy(phenyl)ethanoate	376608-71-8	/	/
Ethanol, 2-[[(3aR,4S,6R,6aS)-6-[[5-aMino-6-chloro-2-(propylthio)-4-pyriMidinyl]aMino]tetrahydro-2,2-diMethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-	376608-74-1	/	/
(1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine hydrochloride	1156491-10-9	/	/
Cyclopropanamine,2-(3,4-difluorophenyl)-(1R,2S) -(2R,3R)-2,3-dihydroxybutanedioate (1:1)	220352-39-6	/	/
2-[[(3aS,4R,6S,6aR)-4-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]oxy]ethanol	274693-26-4	/	/

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态